Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.
WASHINGTON (Reuters) - Medicare will continue coverage of Roche Holdings' drug Avastin for breast cancer regardless of what U.S. health regulators decide about the medicine, a spokesperson for the U.S. health insurer said.
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG had nothing to lose by giving Avastin another roll of the dice, and by doing so showed the world it still believes the drug should be used in breast cancer.
SILVER SPRING, Md. (Reuters) - U.S. health advisers delivered a blow to Roche Holding on Wednesday, voting to reject the use of Roche Holding drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.
FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.
The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.
FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.
Roche/Genentech, maker of Avastin (bevacizumab), has requested a hearing before the U.S. Food and Drug Administration to appeal the agency’s December 2010 decision to withdraw approval of bevacizumab as a treatment for metastatic breast cancer.
CHICAGO (Reuters) - Women with advanced breast cancer who were treated with Roche's Avastin were more likely to develop heart failure than other women, according to an analysis released on Tuesday that raised more concerns about the already troubled drug.
Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.